Humana (NYSE:HUM - Get Free Report) had its target price increased by equities researchers at Morgan Stanley from $370.00 to $475.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has an "equal weight" rating on the insurance provider's stock. Morgan Stanley's price target would suggest a potential upside of 25.96% from the stock's current price.
HUM has been the subject of several other research reports. Monness Crespi & Hardt raised Humana to a "buy" rating in a research report on Friday, October 9th. Weiss Ratings restated a "hold (c)" rating on shares of Humana in a research note on Thursday, November 12th. Cantor Fitzgerald assumed coverage on shares of Humana in a report on Monday. They issued an "overweight" rating for the company. Robert W. Baird raised Humana from a "neutral" rating to an "outperform" rating and upped their target price for the company from $390.00 to $596.00 in a report on Friday, October 9th. Finally, KeyCorp downgraded shares of Humana from an "overweight" rating to a "sector weight" rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Humana has an average rating of "Moderate Buy" and an average target price of $489.35.
Check Out Our Latest Report on Humana
Humana Trading Down 2.2%
Humana stock traded down $8.67 during midday trading on Thursday, reaching $377.11. The stock had a trading volume of 733,380 shares, compared to its average volume of 1,659,462. The stock's 50-day simple moving average is $410.26 and its 200 day simple moving average is $320.44. Humana has a twelve month low of $163.11 and a twelve month high of $462.87. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.65 and a current ratio of 1.65. The stock has a market capitalization of $45.29 billion, a PE ratio of 36.73, a price-to-earnings-growth ratio of 2.11 and a beta of 0.65.
Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Friday, November 6th. The insurance provider reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($1.00) by $0.30. The company had revenue of $41.16 billion for the quarter, compared to the consensus estimate of $40.87 billion. Humana had a return on equity of 8.50% and a net margin of 0.81%. The company's quarterly revenue was up 26.1% compared to the same quarter last year. During the same period last year, the business posted $3.24 EPS. Humana has set its FY 2026 guidance at 9.500- EPS. Analysts expect that Humana will post 9.66 EPS for the current year.
Insiders Place Their Bets
In related news, insider Joseph Ventura sold 5,495 shares of the firm's stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $433.85, for a total transaction of $2,384,005.75. Following the completion of the sale, the insider directly owned 21,910 shares in the company, valued at approximately $9,505,653.50. This trade represents a 20.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.20% of the company's stock.
Hedge Funds Weigh In On Humana
Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in Humana in the 2nd quarter worth approximately $4,138,160,000. State Street Corp lifted its holdings in shares of Humana by 1.6% in the third quarter. State Street Corp now owns 5,543,942 shares of the insurance provider's stock valued at $2,115,402,000 after purchasing an additional 86,870 shares in the last quarter. Pzena Investment Management LLC acquired a new stake in shares of Humana in the second quarter worth $1,749,014,000. Assenagon Asset Management S.A. boosted its position in shares of Humana by 20,126.8% in the third quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider's stock worth $479,053,000 after buying an additional 1,249,272 shares during the period. Finally, Legal & General Group Plc purchased a new position in shares of Humana during the second quarter valued at $329,760,000. Institutional investors and hedge funds own 92.38% of the company's stock.
Key Stories Impacting Humana
These are some of the HUM stories that stood out recently:
- Positive Sentiment: Humana plans a National Gold Card program that would reduce prior-authorization requirements for qualifying providers, potentially easing administrative friction. Humana launches National Gold Card Program to reduce prior authorization
- Positive Sentiment: Recent analyst support offers a counterpoint to the selloff: Royal Bank of Canada upgraded Humana to “Outperform.” The company also recently raised its 2026 adjusted EPS guidance to at least $9.50, according to the reported analysis. Royal Bank Of Canada Upgrades Humana to Outperform
- Negative Sentiment: The main pressure is CMS’s proposed CRUSH rule, which would tighten Medicare Advantage oversight and expand recovery of unsupported risk-adjustment payments. The proposal includes plan-level extrapolation of audit findings; CMS estimates roughly $9 billion in collections per payment year. Because Medicare Advantage is central to Humana’s business, investors may see the measure as a risk to future payments and earnings. The rule is proposed, not final. Humana slides as proposed Medicare Advantage audit crackdown pressures insurers
About Humana
(
Get Free Report)
Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.